MBL2 and breast cancer: Interestingly, breast cancer chemotherapy using the combination of doxorubicin and cyclophosphamide is reported to have a negative impact because the mannose-binding lectin 2 (MBL2) expression in breast cancer patients receiving this combination of drugs is downregulated [70].